HK Stock Market Move | MOBVOI (02438) surged by 40% on high trading volume. The core business revenue of AIGC in the first half of the year increased significantly, highlighting the company's first-mover advantage.
Exit-Enquiry (02438) surged 40% in trading volume, reaching a 40.79% increase at the time of writing, trading at 1.07 Hong Kong dollars with a total transaction value of 12.7073 million Hong Kong dollars.
MOBVOI (02438) surged by 40% on high trading volume, reaching 1.07 Hong Kong dollars as of the release of this report, with a total turnover of 12.7073 million Hong Kong dollars.
In terms of news, MOBVOI's mid-term performance in 2024 showed that the company's overall revenue in the first half of the year was 163 million yuan, with AIGC's main business revenue growing significantly to 92.3 million yuan, an increase of 123.8% year-on-year. From 2022 to 2023 and up to June 30, 2024, the proportion of AIGC revenue to total revenue has continued to increase, reaching 8.0%, 23.2%, and 56.7%, respectively.
Huaxi previously pointed out that the company has a significant first-mover advantage in the AIGC application field, and as the industry space rapidly expands, the flywheel effect is expected to continue. It is anticipated that AIGC-related services will support the company's rapid performance growth, while the enhancement of AIGC capabilities is expected to create synergies with the other two business lines.
Related Articles

CINDA INTL HLDG(00111) purchases bonds with a principal amount totaling 30 million RMB.

NIRAKU (01245) entered into a trust beneficiary transfer agreement with SMFL MIRAI Partners Company.

Jiangsu Hengrui Pharmaceuticals(600276.SH): Injectable drug SHR-1501 included in the list of breakthrough therapies under consideration.
CINDA INTL HLDG(00111) purchases bonds with a principal amount totaling 30 million RMB.

NIRAKU (01245) entered into a trust beneficiary transfer agreement with SMFL MIRAI Partners Company.

Jiangsu Hengrui Pharmaceuticals(600276.SH): Injectable drug SHR-1501 included in the list of breakthrough therapies under consideration.
